Heart and lung monitoring during lung cancer radiation and immunotherapy
Part of Cancer, Lungs & breathing clinical trials.
This study monitors how the heart and lungs respond to radiation therapy combined with immunotherapy for locally advanced lung cancer. It aims to learn how well patients tolerate treatment and to detect early signs of side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You have locally advanced lung cancer (NSCLC or SCLC) and are scheduled for a planned course of radiation (45 Gy or higher) followed by immunotherapy.
- You may receive radiation and immunotherapy even if you are not getting chemotherapy at the same time.
- You are able to care for yourself (ECOG performance status 0, 1, or 2).
- Your doctor estimates you will live at least 6 months.
- You have not had radiation to the chest area before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether a more intensive form of targeted radiation, combined with immunotherapy (immune checkpoint inhibitors), can work better and be safe for people with advanced non-small cell lung cancer. You may be considered if your tumor is limited in size and you’re able to receive both treatments.
This study looks at how chest radiation treatment affects the heart and lungs in people with certain lung or esophagus cancers. It may help doctors better predict and prevent these side effects during curative (aimed at cure) radiotherapy.
This study looks at medical images and health records from people treated with radiation for early-stage non-small cell lung cancer to better understand how radiation affects the heart and lungs. This could help doctors prevent side effects in future patients.
This trial tests an early heart-focused intervention guided by a special heart recording (impedance cardiography) in people with locally advanced, unresectable stage III non-small cell lung cancer. The goal is to improve heart-related safety during planned radiation and chemotherapy, with or without immunotherapy.
This study looks at using blood and imaging markers to predict if patients with lung cancer who receive both immunotherapy and chest radiation will develop lung inflammation (called radiation lung injury). It may help doctors personalise care and reduce side effects.
This trial studies treatment that combines chemotherapy and radiation for people with advanced lung cancer that cannot be removed with surgery. It may help improve cure chances for patients who can complete the study tests, including heart scans.
Hear when a new Lung cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.